merck stapled peptide p53 patent stapled p53 peptide - men-s-peptide-supplements prevents MDM2 from suppressing wild-type p53 Merck Stapled Peptide p53 Patent: Advancing Cancer Therapy Through Protein-Protein Interaction Inhibition

mersacidin-total-synthesis-solid-phase-peptide-synthesis The development of novel cancer therapeutics is a dynamic field, with a significant focus on targeting protein-protein interactions (PPIs) that drive disease progression作者：YS Chang·2013·被引用次数：812—We report a potent and selective dual inhibitor of MDM2 and MDMX, ATSP-7041, which effectively activates thep53pathway in tumors in vitro and in vivo.. Among the most promising strategies is the use of stapled peptides, a class of molecules designed to mimic natural protein structures while offering enhanced stability and cell permeability. This article delves into the landscape of Merck stapled peptide p53 patent filings and related research, exploring how these innovations aim to harness the power of the p53 tumor suppressor protein and its regulators to combat cancer.

Understanding the p53 Pathway and its Perturbation in Cancer

The p53 protein, often referred to as the "guardian of the genome," plays a critical role in maintaining genomic stability. It acts as a transcription factor that responds to cellular stress, such as DNA damage, by initiating cellular responses like cell cycle arrest, DNA repair, or apoptosis (programmed cell death)Tumor-Targeted Delivery of the p53-Activating Peptide .... This crucial function makes p53 a vital tumor suppressor protein.

In a significant proportion of human cancers, the p53 pathway is inactivated, either through mutations in the p53 gene itself or through the overexpression of its negative regulators. Two key negative regulators are the E3 ubiquitin ligases MDM2 and MDMX (also known as MDM2 and MDM4). These proteins bind to p53, marking it for degradation and thereby diminishing its tumor-suppressive activity. Reactivating the p53 tumor suppressor pathway by inhibiting the p53-MDM2 interaction is therefore a highly sought-after therapeutic strategy.Stapled peptide reactivates p53

The Rise of Stapled Peptides for p53 Activation

Traditional peptide-based therapeutics often face challenges due to their susceptibility to proteolytic degradation and poor cell penetration. Stapled peptides represent a significant advancement by introducing a covalent cross-link, or "staple," into the peptide backbone. This modification stabilizes the peptide's α-helical conformation, which is crucial for binding to key protein targets. This structural enhancement not only improves pharmacokinetic properties but also unlocks their potential for therapeutic applications.A therapeutic patent overview of MDM2/X-targeted ...

Research and patent filings surrounding Merck stapled peptide p53 patent initiatives highlight the company's commitment to this area.2024年1月12日—Althoughstapledα-helicalpeptidescan address challenging targets, their advancement is impeded by poor understandings for making them ... These stapled peptides are designed to mimic the p53 protein's interaction domain that binds to MDM2 and MDMX.Stapled peptides with improved potency and specificity that ... By doing so, they effectively disrupt the p53-MDM2 and p53-MDMX protein-protein interactions, preventing MDM2 from suppressing wild-type p53 and ultimately leading to the reactivation of the p53 tumor suppressor pathway.

Key Developments and Innovations in Stapled Peptide Technology

The scientific literature and patent landscape reveal several key innovations in the field of stapled peptides for p53 activation:

* Mimicking the p53 Alpha-Helix: Many stapled peptides are engineered to precisely mimic the biologically active α-helical conformation of the p53 protein.Design-Rules for Stapled Alpha-Helical Peptides with On- ... This design strategy ensures potent and specific binding to the target proteins. For example, the compound ALRN-6924 is described as a cell-penetrating stapled alpha-helical peptide designed to equipotently disrupt the interaction between the p53 tumor suppressor protein and its negative regulators. ALRN-6924 has advanced to clinical trials, signifying the therapeutic potential of this approach.Stereoisomerism of stapled peptide inhibitors of the p53 ...

* Non-Membrane Disruptive Peptides: A notable advancement is the development of non-membrane disruptive p53 activating stapled peptides.作者：S Crunkhorn·2013·被引用次数：10—The authors developed a stable hydrocarbon-stapledα-helicalpeptidetherapeutic, based on the biologically active α-helical conformation found ... This characteristic is important for improving cellular uptake and reducing potential off-target effects, making these peptides safer and more effective. The patent literature frequently features "non-membrane disruptive and p53 activating stapled peptides," underscoring the focus on optimizing delivery and minimizing toxicityA therapeutic patent overview of MDM2/X-targeted ....

* Dual Inhibitors: Some research explores stapled peptides as dual inhibitors of MDM2 and MDMX. Compounds like ATSP-7041 have been reported as potent and selective dual inhibitors that effectively activate the p53 pathway in tumors both in vitro and in vivo作者：YS Chang·2013·被引用次数：812—We report a potent and selective dual inhibitor of MDM2 and MDMX, ATSP-7041, which effectively activates thep53pathway in tumors in vitro and in vivo.. The development of such stapled peptide-based radiotheranostic agents is also an area of interest, aiming to combine diagnostic imaging with targeted radiotherapy for p53 mutant cancersStapled Peptides with Improved Potency and Specificity ....

* Design Rules and Optimization: Significant effort is being invested in understanding the "design rules" for stapled peptides to ensure efficacy in vivo.(12) United States Patent - Googleapis.com Research into design-rules for stapled peptides with in vivo activity aims to optimize potency, specificity, and pharmacokinetic profiles.a potent dual inhibitor of MDM2 and MDMX for p53- ... This includes exploring the use of both L- and D-amino acids to create molecules that bind to Mdm2 and MdmX to displace p53.

* Therapeutic Potential and Patent Landscape: The merck stapled peptide p53 patent filings reflect a broader trend of pharmaceutical companies exploring this modality(12) United States Patent - Googleapis.com. Patents like US9527896B2 - Stabilized p53 peptides and uses thereof and US9517252B2 - p53 activating peptides indicate a strong intellectual property focus on these innovative compounds. The development of a stapled α-helical peptide lead molecule for treating cancers with an intact p53 tumor suppressor pathway is a testament to the therapeutic promise.

Future Directions and Conclusion

The field of stapled peptides, particularly in the context of p53 pathway reactivation, is rapidly evolving.作者：S Crunkhorn·2013·被引用次数：10—The authors developed a stable hydrocarbon-stapledα-helicalpeptidetherapeutic, based on the biologically active α-helical conformation found ... Ongoing research aims to further refine the design and delivery of these peptides, leading to improved potency and specificity.Tumor-Targeted Delivery of the p53-Activating Peptide ... Innovations in areas like targeted delivery of the p53-activating peptide and the development of functionalized double strain-promoted stapled peptides are paving the way for next-generation cancer therapies.

In conclusion, the exploration of merck stapled peptide p53 patent activity and the broader scientific literature demonstrates a robust effort to leverage the power of stapled peptides to restore the function of the critical p53 tumor suppressor. By effectively inhibiting the p53-MDM2 interaction, these sophisticated molecules hold significant promise for developing novel and effective treatments for a wide range of cancers.Stapled peptides as scaffolds for developing radiotracers ... The continued investigation into stapled peptides and their ability to prevent MDM2 from suppressing wild-type p53 marks a significant step forward in oncological research and development. The ultimate goal is to translate these scientific breakthroughs into tangible benefits for patients battling cancer.